Bausch + Lomb (BLCO) is set to feature prominently at the American Society of Cataract and Refractive Surgery meeting in Washington, D.C., where forty-five presentations will spotlight studies across its surgical, vision care, and pharmaceutical portfolio.
See our latest analysis for Bausch + Lomb.
The ASCRS spotlight comes as Bausch + Lomb’s 7 day share price return of 7.08% contrasts with a 30 day share price return decline of 4.22% and a 1 year total shareholder return of 37.66%. This suggests momentum has recently picked up after a softer start to the year.
If you are looking for more ideas in eye care and medical technology, it could be a good moment to scan the market using our curated list of 37 healthcare AI stocks.
With shares recently at US$16.34, an intrinsic value estimate suggesting a 54% discount and analyst targets about 13% higher, you have to ask: is Bausch + Lomb still undervalued, or is the market already pricing in future growth?
Most Popular Narrative: 58.3% Undervalued
At a last close of $16.34 against a fair value narrative of $39.23, the gap between price and perceived worth is hard to ignore.
For more than a week following the company’s Annual General Meeting (AGM), shareholders have been left without a single published result, filing, press release, or confirmation of what occurred inside the meeting. This absence of disclosure is not normal, not industry standard, and not aligned with the obligations of a publicly traded company. Read the complete narrative.
The story behind that $39.23 fair value hinges on how fast losses could reverse, how margins might evolve, and what kind of future earnings multiple could be justified. The tension between current losses and a much higher projected valuation is at the core of this narrative, and the details explain why some investors see a large gap between price and potential.
Result: Fair Value of $39.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this undervaluation story could be challenged if governance concerns around the AGM linger, or if continued net losses of US$360 million reshape how risk is priced.
Find out about the key risks to this Bausch + Lomb narrative.
Next Steps
If this all sounds conflicted, that is the point. The data can support different views, so it makes sense to move quickly and check the 3 key rewards
Looking for more investment ideas?
If Bausch + Lomb has caught your attention, do not stop there. Widen your search with a few carefully selected stock ideas that could broaden your watchlist.
- Target higher quality at sensible prices by scanning our collection of 62 high quality undervalued stocks that pair fundamentals with appealing valuations.
- Prioritise resilience by reviewing 68 resilient stocks with low risk scores that score well on stability and business risk.
- Spot early opportunities by checking the screener containing 25 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com